Molecular Partners (MOLN) and Orano Med said Tuesday that the latest preclinical data on their MP0712 product candidate confirmed "high tumor uptake" while keeping low kidney exposure.

The companies co-developed MP0712 as a radio-designed ankyrin repeat protein therapeutic candidate that targets delta-like ligand 3, according to the statement.

Molecular Partners and Orano Med said the latest data showed strong uptake by the targeted tissue, with minimal impact on health tissues. Dose-range finding studies in mice also confirmed that the treatment was well tolerated at relevant dosage.

The companies said they plan to start first-in-human studies in 2025, with initial clinical data on MP0712 expected within the same year.

Molecular Partners shares were up over 10% premarket.

Price: 7.47, Change: +0.69, Percent Change: +10.18